within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AX09_DiroximelFumarate;

model DiroximelFumarate
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.64,
    Cl = 1.0555555555555555e-05,
    adminDuration = 600,
    adminMass = 231 / 1000000,
    adminCount = 1,
    Vd = 0.072,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.006666666666666667,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>DiroximelFumarate</td></tr><tr><td>ATC code:</td><td>L04AX09</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>231</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>72</td><td>L</td></tr>
    <tr><td>clearance:</td><td>38</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Diroximel fumarate is an oral immunomodulatory drug used for the treatment of relapsing forms of multiple sclerosis (MS). It is a prodrug that is rapidly converted to monomethyl fumarate (MMF), the active metabolite which exerts anti-inflammatory and neuroprotective effects. It is an FDA- and EMA-approved medication as of 2019 and is currently in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult volunteers (fasted/fed), reporting on monomethyl fumarate (active metabolite) following 231 mg diroximel fumarate twice daily oral administration.</p><h4>References</h4><ol><li><p>Kuchimanchi, M, et al., &amp; Penner, N (2022). Development of a Population Pharmacokinetic Model for the Diroximel Fumarate Metabolites Monomethyl Fumarate and 2-Hydroxyethyl Succinimide Following Oral Administration of Diroximel Fumarate in Healthy Participants and Patients with Multiple Sclerosis. <i>Neurology and therapy</i> 11(1) 353–371. DOI:<a href=\"https://doi.org/10.1007/s40120-021-00316-6\">10.1007/s40120-021-00316-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35041178/\">https://pubmed.ncbi.nlm.nih.gov/35041178</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L04AX09 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end DiroximelFumarate;
